185 related articles for article (PubMed ID: 20978914)
1. Understanding the structure-activity relationship of betulinic acid derivatives as anti-HIV-1 agents by using 3D-QSAR and docking.
Lan P; Chen WN; Huang ZJ; Sun PH; Chen WM
J Mol Model; 2011 Jul; 17(7):1643-59. PubMed ID: 20978914
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Structure-activity Relationship Study of Betulinic Acid Derivatives Against HIV using SMILES-based Descriptors.
Worachartcheewan A; Toropova AP; Toropov AA; Siriwong S; Prapojanasomboon J; Prachayasittikul V; Nantasenamat C
Curr Comput Aided Drug Des; 2018; 14(2):152-159. PubMed ID: 29332601
[TBL] [Abstract][Full Text] [Related]
3. A 3D-QSAR Study on Betulinic Acid Derivatives as Anti-Tumor Agents and the Synthesis of Novel Derivatives for Modeling Validation.
Ding W; Zhang S; Zhu M; Wang S; Xu T; Qu H; Yu T; Yan X; Wang Y
Anticancer Agents Med Chem; 2017; 17(4):566-575. PubMed ID: 27658994
[TBL] [Abstract][Full Text] [Related]
4. Structure and Anti-HIV Activity of Betulinic Acid Analogues.
Huang QX; Chen HF; Luo XR; Zhang YX; Yao X; Zheng X
Curr Med Sci; 2018 Jun; 38(3):387-397. PubMed ID: 30074203
[TBL] [Abstract][Full Text] [Related]
5. Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.
Huang L; Yuan X; Aiken C; Chen CH
Antimicrob Agents Chemother; 2004 Feb; 48(2):663-5. PubMed ID: 14742233
[TBL] [Abstract][Full Text] [Related]
6. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
Lai W; Huang L; Ho P; Li Z; Montefiori D; Chen CH
Antimicrob Agents Chemother; 2008 Jan; 52(1):128-36. PubMed ID: 17954689
[TBL] [Abstract][Full Text] [Related]
7. Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
Dang Z; Lai W; Qian K; Ho P; Lee KH; Chen CH; Huang L
J Med Chem; 2009 Dec; 52(23):7887-91. PubMed ID: 19526990
[TBL] [Abstract][Full Text] [Related]
8. A 3D QSAR study of betulinic acid derivatives as anti-tumor agents using topomer CoMFA: model building studies and experimental verification.
Ding W; Sun M; Luo S; Xu T; Cao Y; Yan X; Wang Y
Molecules; 2013 Aug; 18(9):10228-41. PubMed ID: 23973995
[TBL] [Abstract][Full Text] [Related]
9. Design of novel DABO derivatives as HIV-1 RT inhibitors using molecular docking, molecular dynamics simulations and ADMET properties.
Zhang Y; Chen L; Wang Z; Zhu Y; Jiang H; Xu J; Xiong F
J Biomol Struct Dyn; 2024 May; 42(8):4196-4213. PubMed ID: 37272892
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and anti-HIV activity of 3-alkylamido-3-deoxy-betulinic acid derivatives.
Kashiwada Y; Chiyo J; Ikeshiro Y; Nagao T; Okabe H; Cosentino LM; Fowke K; Morris-Natschke SL; Lee KH
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1387-90. PubMed ID: 10993248
[TBL] [Abstract][Full Text] [Related]
11. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors.
Qian K; Kuo RY; Chen CH; Huang L; Morris-Natschke SL; Lee KH
J Med Chem; 2010 Apr; 53(8):3133-41. PubMed ID: 20329730
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors.
Khedkar VM; Ambre PK; Verma J; Shaikh MS; Pissurlenkar RR; Coutinho EC
J Mol Model; 2010 Jul; 16(7):1251-68. PubMed ID: 20069323
[TBL] [Abstract][Full Text] [Related]
13. A review of natural and modified betulinic, ursolic and echinocystic acid derivatives as potential antitumor and anti-HIV agents.
Baglin I; Mitaine-Offer AC; Nour M; Tan K; Cavé C; Lacaille-Dubois MA
Mini Rev Med Chem; 2003 Sep; 3(6):525-39. PubMed ID: 12871156
[TBL] [Abstract][Full Text] [Related]
14. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
Teixeira C; Serradji N; Maurel F; Barbault F
Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
[TBL] [Abstract][Full Text] [Related]
15. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
Xu HR; Fu L; Zhan P; Liu XY
SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
[TBL] [Abstract][Full Text] [Related]
17. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
Durdagi S; Mavromoustakos T; Papadopoulos MG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors.
Zhao Y; Chen CH; Morris-Natschke SL; Lee KH
Eur J Med Chem; 2021 Apr; 215():113287. PubMed ID: 33639343
[TBL] [Abstract][Full Text] [Related]
19. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.
Buolamwini JK; Assefa H
J Med Chem; 2002 Feb; 45(4):841-52. PubMed ID: 11831895
[TBL] [Abstract][Full Text] [Related]
20. The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation.
Chen Y; Sit SY; Chen J; Swidorski JJ; Liu Z; Sin N; Venables BL; Parker DD; Nowicka-Sans B; Lin Z; Li Z; Terry BJ; Protack T; Rahematpura S; Hanumegowda U; Jenkins S; Krystal M; Dicker ID; Meanwell NA; Regueiro-Ren A
Bioorg Med Chem Lett; 2018 May; 28(9):1550-1557. PubMed ID: 29631960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
